TRUMENBA DIN 02468751
Status: Marketed
Holder: PFIZER CANADA ULC
Available to quote
Health Canada record
| Active ingredient(s) | NEISSERIA MENINGITIDIS GRP B RECOMBINANT LIPOPROTEIN 2086 SUBFAMILY A 60 MCG; NEISSERIA MENINGITIDIS GRP B RECOMBINANT LIPOPROTEIN 2086 SUBFAMILY B 60 MCG |
|---|---|
| Dosage form | Suspension |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07AH MENINGOCOCCAL VACCINES |
| Original market date | 31-Jan-2018 |
| Current status date | 31-Jan-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19881 | 2017-10-05 | New Drug Submission (NDS) |